Celldex Therapeutics said on Tuesday its experimental drug significantly reduced disease activity in two late-stage trials of patients with a chronic skin condition, clearing a key hurdle toward a U.S. regulatory filing.
Shares of the New Jersey-based company fell nearly 15% as investors focused on two cases of probable anaphylaxis reported in the studies.
